The Peggy Lillis Foundation's CEO and Co-founder Christian Lillis discusses the organization's initiatives for C diff month, and offers a glimpse of the upcoming Scientific Symposium they are hosting next week.
News|Articles|June 28, 2024
Insights from Recent Studies on Advancements in C difficile Treatment and Management
Author(s)Sophia Abene
DDW 2024 highlighted advances in managing recurrent C difficile infections, emphasis on the effectiveness of live biotherapeutic products and the impact of antibiotic stewardship, and more ongoing efforts in combating C difficile.
Advertisement
Presented at DDW 2024 by Ken Blount, the effectiveness of live biotherapeutic products in treating recurrent C difficile infections (rCDI), offers insights into microbiota alteration and prospects for management.
In a 17-year study across 2 Québec hospitals, researchers explored the relationship between antibiotic use and healthcare-associated C difficile infections.
In a small study, rCDI therapy, Rebyota, was durable in a majority of patients who were exposed to non-CDI antibiotics.
Researchers assess the efficacy of fecal microbiota transplantation (FMT) for first or second episodes of C difficile infection (CDI), demonstrating high initial cure rates and sustained in managing the condition.
A case study of an 80-year-old patient, illustrating successful management of dual H pylori and C diff infections with quadruple therapy, with key insights from Yazan Abboud, MD and Sima Vossough-Teehan, MD.
A Florida hospital takes a novel approach to healthcare-associated infection and reduces inappropriate testing by setting up guidelines.
Advertisement
Related to this article
The Pan American Health Organization has reportedly revoked the US measles elimination status after more than 12 months of continuous transmission, as 2026 cases top 5,400, states report 10 deaths, and kindergarten MMR coverage has fallen to 92.4%.
The latest CDC numbers show a 4.4% increase of measles cases from week-to-week. Hospitalizations have reached 591, or 11% of all 2026 cases, and the Pan American Health Organization is deciding this week whether the United States has lost its measles elimination status.
Here is some important information around this pathogen and the intestinal infection.
Los Angeles has been experiencing this challenging bacteria in recent years with the potential of it becoming carbapenem-resistant in the future. Shaun Yang, PhD, D(ABMM), FIDSA, MLS(ASCP), provides commentary about his team's work in this area and the role of genomic sequencing to uncover this troublesome pathogen.
Enteric fever (typhoid or paratyphoid fever) infection in travelers returning to the US is likely resistant to ciprofloxacin, and with some cases also resistant to ceftriaxone, CDC investigators advise treatment guided by susceptibility.
The 2026 Antimicrobial Resistance Threats Report from the CDC categorizes 19 bacterial and fungal pathogens by level of threat to health in the US.
Darren Gitelman, MD, senior medical director of the Advocate Memory Center in Park Ridge, discusses findings linking high-dose influenza vaccination to lower Alzheimer disease risk, study limitations, and potential implications for future dementia prevention research.
Advertisement
Advertisement
Trending on Contagion Live
1
Reports Say US Loses Measles Elimination Status After 26 Years
2
Peggy Lillis Foundation Expands C diff Campaign to Pediatric Population, Survivors
3
Measles Update: November 13, 2026
4
Cefepime-Zidebactam, a Novel Option for AMR Infections
5